IP Library Granted Patent US 9,192,586
Granted Patent B2
US 9,192,586 · App. 10/746,403 · Granted Nov 24, 2015

Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders

Inventor: Dennis L. Gierhart (Chesterfield, MO)
Assignee: ZeaVision LLC
A61K31/047A61K31/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,192,586
App. No.
10/746,403
Granted
Nov 24, 2015
Kind
B2
Abstract

Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

Claims (13)

1. A nutrient formulation in a unit dosage or daily dosage form for oral ingestion, wherein a recommended daily dosage of said nutrient formulation comprises:

a. at least 3 milligrams of zeaxanthin, which is present in 3R-3′R stereoisomer form and is substantially free of meso-zeaxanthin stereoisomers;

b. zinc at a dosage that (i) does not exceed 40 milligrams of elemental zinc and (ii) does not require a copper additive to the formulation to inhibit zinc-induced anemia;

c. vitamin C;

d. at least one tocopherol with anti-oxidant activity; and

wherein the nutrient formulation is provided in the form selected from the group consisting of capsules, tablets, liquids, and powders for oral ingestion.

2. The nutrient formulation of claim 1 , wherein said nutrient formulation is present in a form that provides sustained release over a span of at least 3 hours following ingestion.

3. The nutrient formulation of claim 1 , wherein said formulation also comprises at least one agent that has been added to increase digestive uptake of lipophilic compounds.

4. The nutrient formulation of claim 1 , wherein the formulation is in the form of capsules containing oily carrier materials.

5. The nutrient formulation of claim 1 , wherein the vitamin C is in the form of absorbic acid.

6. The nutrient formulation of claim 1 , further comprising lipoic acid and omega-3 fatty acids.

7. The nutrient formulation of claim 1 , wherein the daily dosage of zeaxanthin is at least 10 milligrams.

8. The nutrient formulation of claim 1 , wherein the formulation is in the form of a capsule, and a plurality of capsules are required to achieve the at least 3 milligram daily dosage of zeaxanthin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2025
From: ZEAVISION LLC
To: PRN PHYSICIAN RECOMMENDED NUTRICEUTICALS LLC
Reel/Frame 071860/0484 →
SUPPLEMENT TO PATENT SECURITY AGREEMENT Recorded Dec 20, 2024
From: ZEAVISION, LLC; OCULAR PROGNOSTICS, LLC
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 069743/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2006
From: GIERHART, DENNIS L.
To: ZEAVISION, LLC.
Reel/Frame 018122/0692 →
Continuity (2)
Provisional Application 60453522 · Mar 10, 2003
Related Publication 20050147648A1 · Jul 7, 2005